- Open Access
Trends in antibiotic susceptibility patterns and epidemiology of MRSA isolates from several hospitals in Riyadh, Saudi Arabia
© Baddour et al; licensee BioMed Central Ltd. 2006
- Received: 11 September 2006
- Accepted: 02 December 2006
- Published: 02 December 2006
Methicillin-resistant Staphylococcus aureus (MRSA), is associated with high morbidity and mortality rates with rapid development of resistance.
A total of 512 MRSA isolates were procured from 6 major hospitals in Riyadh, Saudi Arabia and antibiotic susceptibilities and MICs were documented against several antibiotics and vancomycin. SPSS version 10 was used for statistical analysis.
The prevalence of MRSA in the study hospitals ranged from 12% to 49.4%. Mean patient age was 44 years with males constituting 64.4% and females 35.6%. Approximately 41.5% of the isolates came from patients in the extreme age groups. MIC for vancomycin was in the susceptible range for all isolates ranging from 0.25 to 3 ug/ml. The overall susceptibility of MRSA to the various antibiotics tested was: fusidic acid 4.3%, sulfamethoxazole/trimethoprim 33.8%, gentamicin 39.6%, mupirocin 77.0%, gatifloxacin 78.9%, chloramphenicl 80.7%, linezolid 95.1%, quinupristin/dalfopristin 100%. Some differences were noted in the resistance of isolates among the participating hospitals reflecting antibiotic usage. On the whole, inpatient isolates (accounting for 77.5% of the isolates) were more resistant than outpatient isolates (22.5%) except for linezolid. Quinupristin-dalfopristin and linezolid are the most effective antibiotics tested against inpatient isolates while quinupristin-dalfopristin and gatifloxacin seem to be the most effective against outpatient isolates.
Approximately one forth of the isolates are no longer susceptible to mupirocin used for eradication of the carrier state reflecting resistance developing after widespread use. Trends over time show a tendency towards decreased susceptibility to gatifloxacin and linezolid with increasing susceptibility to gentamicin and sulfamethoxazole/trimethoprim.
Quinupristin/dalfopristin and linezolid are two valuable additions to our antimicrobial armamentarium, but resistance has already been described. To preserve their value, their use should be limited to those rare cases where they are clearly needed. Fusidic acid, the local antibiotic, gentamicin and trimethoprim/sulfamethoxazole should not be relied upon for treatment of MRSA infections, at least empirically as the percentage of susceptible isolates is very low.
- Methicillin Resistant Staphylococcus Aureus
Staphylococcus aureus (S. aureus) is a major pathogen associated with serious community- and hospital-acquired diseases. Most of S. aureus infections are caused by methicillin sensitive Staphylococcus aureus strains (MSSA) that are susceptible to all other classes of anti-staphylococcal antibiotics. Methicillin resistant Staphylococcus aureus strains (MRSA) are implicated in serious infections and nosocomial outbreaks. These strains show resistance to a wide range of antibiotics, thus limiting the treatment options to very few agents such as vancomycin and teicoplanin[1, 2].
Microbes have genetic plasticity, which means that they have the capacity to evolve in response to their environment. The major impetus for developing resistance is selective pressure resulting from antibiotic use. The bacteria that survive are those that develop mechanisms to avoid being killed by antibiotics. The treatment of several pathogens, including MRSA, is problematic. New solutions are needed to preserve the activity of our current antibiotic armamentarium, to lower the overall risk of bacterial resistance and to successfully treat patients with resistant bacterial infections. Options include: development of new antibiotics to treat resistant organisms; vaccination to prevent infections; and improved use of antibiotics. Because bacteria will eventually develop means to avoid being killed by antibiotics, judicious use of antibiotics by all clinicians is imperative. Appropriate antibiotic use involves selection of a "targeted spectrum" antibiotic, as well as an appropriate dose and duration. This entails updated databases on the antibiotic susceptibility of such databases to new as well as traditional antibiotics.
Because the mechanism of resistance is an alteration in the target of the antibiotic, MRSA are resistant clinically to all beta-lactam antibiotics, even though a drug such as cefazolin may appear to be active in vitro. It is also important to note that MRSA are often multidrug-resistant and are resistant to antibiotics such as the macrolides and aminoglycosides, even though the mechanisms of action of these antibiotics are different than that of the beta lactams.
Clinical isolates of MRSA that are intermediate to vancomycin, called vancomycin-intermediate Staphylococcus aureus (VISA), were first identified in patients in Japan in 1996. As of June 2002, 8 VISA infections had been documented in patients in the US. Vancomycin has a narrow spectrum of activity, restricted to most Gram-positive bacteria, and is the drug of choice for the treatment of (MRSA). The vancomycin MIC for MRSA is 1–2 mg/L for fully vancomycin-susceptible strains. Vancomycin inhibits peptidoglycan synthesis by binding to the D-Ala-D-Ala terminus of the nascent murein monomer, resulting in the inhibition of cell-wall synthesis. Only 50% of the vancomycin arriving at the surface of a staphylococcus will reach the target site. VISA are characterized by a thicker cell-wall with increased amounts of peptidoglycan, and the increased quantities of unprocessed D-Ala-D-Ala cause increased 'trapping' and 'clogging', resulting in higher vancomycin MICs of 8–16 μg/ml and the increased inoculum effect observed with VISA in comparison with fully vancomycin-susceptible strains.
In June 2002 the first clinical isolate of vancomycin resistant Staphylococcus aureus (VRSA) was reported from a patient in Michigan. The term VRSA is based on the vancomycin breakpoint of the British Society for Chemotherapy, where a strain for which the MIC is 8 mg/liter is defined as resistant. Since the same MIC is defined as indicating intermediate susceptibility by the NCCLS, these VRSA strains are called vancomycin-intermediate Staphylococcus aureus or glycopeptide-intermediate Staphylococcus aureus in the United States.
Early observations from both clinical isolates and laboratory-derived strains of GISA have focused on the bacterial cell wall, where the glycopeptides exert their antimicrobial effect. The glycopeptides prevent the transglycosylation and transpeptidation reactions necessary for the formation of mature cell wall in Gram positive bacteria. Specifically, they bind to the D-alanyl-D-alanine terminus of the N-acetylmuramyl pentapeptide subunit of the nascent cell wall. On the basis of these and other observations, Sieradzki et al. (1999), proposed a functional model in which glycopeptide molecules are first "captured" in the cell wall, then serve to block access of other glycopeptide molecules to nascent cell wall elements. Additional investigation of laboratory derived vancomycin-resistant strains demonstrated down-regulation of certain penicillin-binding proteins, including PBP2A.
Quinupristin/dalfopristin (Synercid) is a semisynthetic antibiotic that combines two streptogramin compounds in a 30:70 ratio, quinupristin (a group B streptogramin) and dalfopristin (a group A streptogramin), and is the first licensed antibiotic in its class. It inhibits bacterial protein synthesis by binding of each component to a different site on the 50S subunit of the bacterial ribosome, dalfopristin leading to a conformational change in the ribosome which increases the affinity of the ribosome for quinupristin. Each of the two streptogramins separately acts as a bacteriostatic agent but in combination they are bactericidal.
Quinupristin/dalfopristin is available only as an intravenous product. Its spectrum of activity is similar to that of vancomycin, with excellent activity against Gram positive pathogens, including many resistant strains, such as MRSA. Its major value is that it provides a therapeutic option for infections caused by vancomycin-resistant Enterococcus faecium, VISA or VRSA. Unfortunately there are already reports of VRE and MRSA resistant to quinupristin/dalfopristin since its licensure in 1999[10, 11].
Linezolid (Zyvox) is the first licensed oxazolidinone antibiotic. The oxazolidinones, synthetic compounds unrelated to other antimicrobials, inhibit bacterial protein synthesis by binding to the ribosome 50S subunit, thus blocking the initiation complex formation. Linezolid has limited activity against selected Gram-negatives and anaerobes but is highly active against Gram-positive bacteria, including resistant strains. Like quinupristin/dalfopristin, linezolid is active against MRSA, but is only bacteriostatic. Linezolid is available in both intravenous and oral preparations and is 100% bioavailable after oral administration. As such it provides an oral therapeutic option for patients with Gram-positive infections resistant to other oral antibiotics. Linezolid lacks cross-resistance to any other group of antibiotics. Since linezolid became available in 2000, clinical isolates of VRE and MRSA resistant to linezolid have been reported from treated patients [12–14].
Although the fluoroquinolones are not new antibiotics, many studies are still being conducted to assess their uses. Important features of this drug class include excellent bioavailability after oral administration, achievement of high tissue concentrations and a broad spectrum of activity. In general fluoroquinolones are active against many Gram-positive bacteria. They do not appear to be affected by β-lactamase enzymes or altered penicillin binding proteins. The quinolones have a unique mechanism of action; they inhibit two bacterial enzymes, DNA gyrase and topoisomerase IV, that are essential for bacterial DNA synthesis. Because they target bacterial sites distinct from the site of action of other antibiotics, it was hypothesized by some that resistance might be less likely to occur or slower to develop. Unfortunately these hopes were not borne out.
Mupirocin is a naturally occurring agent produced by Pseudomonas fluorescens and has successfully been used to reduce substantially the nasal and hand carriage of MRSA[16, 17]. This regimen is least effective in patients with either indwelling catheters or lesions on their skin. Mupirocin (pseudomonic acid) specifically binds to bacterial isoleucyl-tRNA synthetase (IRS) and inhibits protein synthesis. However, emergence of mupirocin-resistant MRSA strains as a result of long-term and intermittent usage of the antibiotic has also been reported[19, 20]. Repeated courses of topical antimicrobial treatment should be discouraged as they often lead to emergence of strains of bacteria that are resistant to these agents. However, Fawley et al, 2006 provide evidence that short-term mupirocin prophylaxis may be helpful in the prevention of S. aureus surgical site infections with little chance of risk of resistance selection.
Extensive anecdotal data support the use of trimethoprim/sulfamethoxazole for infections caused by MRSA, but only one randomized clinical trial has demonstrated its efficacy for such infections.
A detailed knowledge of the susceptibility to antimicrobial agents is necessary to facilitate the development of effective strategies to combat the growing problem of resistance. A nationwide knowledge base is also important for optimal patient management, control of nosocomial infection and for the conservation of antibiotics. This study was thus designed to track the resistance trends of MRSA isolates from different hospitals to the non-beta-lactams that are commonly used to combat infections by it.
Five hundred and twelve MRSA isolates were consecutively procured from samples submitted to the microbiology labs from patients being treated in several tertiary care hospitals with different geographical locations within Riyadh. The hospitals were designated the code names Hospitals A to F. The names of the hospitals were not stated for privacy reasons and are available from the authors upon request. Isolates were collected during the period from January 2004 through December 2005. No duplicate isolates from the same patient and no environmental strains were included in this study. The methicillin resistant S. aureus ATCC 33591 was included as a reference strain for quality control. Isolates were identified as S. aureus by the standard microbiological procedures. Then the following tests were carried out:
I- Detection of methicillin resistance
This was carried out according to NCCLS guidelines using Oxacillin agar screen test whereby all MRSA isolates were spot inoculated onto Mueller-Hinton agar supplemented with 6 μg/ml oxacillin and 4% NaCl, from a 0.5 McFarland standard suspension. The plates were incubated at 35°C for 24 h as recommended by the Clinical Laboratory Standards Institute (CLSI), formerly NCCLS. If any growth (more than one colony) was detected, the isolate was considered oxacillin or methicillin resistant.
II- Surveillance of MRSA with decreased vancomycin susceptibility
Vancomycin resistance was tested for by vancomycin agar screening test whereby MRSA isolates were spot inoculated onto Mueller Hinton agar supplemented with 6 μg/ml of vancomycin from a 0.5 McFarland standard suspension. The plates were incubated at 35°C for 24 h as recommended by the NCCLS. Any isolates growing two or more colonies on this agar would be considered as positive.
III- Evaluation of Antibiotic susceptibility patterns
Various antibiotics including traditional as well as recently introduced ones were used in disc diffusion tests (Oxoid) according to NCCLS guidelines against all isolates to determine the susceptibility of these isolates to such antibiotics.
The antibiotics tested included: gatifloxacin, gentamicin, linezolid, quinupristin-dalfopristin, mupirocin, fusidic acid, chloramphenicol and trimethoprim-sulfamethoxazole.
IV- MIC determination
Determination of the MIC against vancomycin to detect any isolate with a decreased susceptibility to the drug using E-test (AB-Biodisk, Solna, Sweden). The tests were performed according to the manufacturer's instructions. E-test for the other tested antimicrobials except fusidic acid and chloramphenicol as well as E-test for minocycline were performed for select susceptible strains of MRSA to give an idea about the MIC in our tested isolates.
Statistical package for social sciences (SPSS) version 10 was used to analyze our data. Comparison of categorical variables and percentages between groups was done by the Pearson chi-square test or Fisher's exact test, as appropriate. Logistic regression analysis was carried out to find association between variables. The threshold for a significant difference was designated a P value of <0.005. All tests were two tailed.
MRSA isolates from inpatients accounted for 77.5% of the isolates (397/512), while 22.5% came from outpatients (115/512). Inpatient isolates were distributed in the following services: ICU: 96 (24.2%), Medicine: 59 (14.9%), Surgery: 54 (13.6%), Pediatric: 48 (12.1%), Burn & Plastic Surgery: 29 (7.3%), Orthopedic Surgery: 27 (6.8%), Renal: 18 (4.5%) & other unspecified wards: 66 (16.6%). Most isolates came from wounds (39.7%) followed by soft tissues (28.4%).
Regarding the gender distribution of the isolates, 64.4% were recovered from male patients while 35.6% were from females. These values are quite similar to those reported by van Belkum et al, 1997 from King Faisal Specialist hospital – which was one of the hospitals included in the present study – isolated from patients referred to it from several other hospitals in Saudi Arabia. They report procurement of 66% of their isolates from male patients and 34% from females. Madani et al, 2001 also report a 65.8% recovery from males and 34.2% from females in Saudi Arabia. Similarly, from the eastern province of Saudi Arabia, Bukharie & Abdelhadi (2001) report 63% of MRSA isolation from males and 37% from females so this probably reflects the distribution of MRSA throughout the Kingdom with a male patient predominance most likely due to the fact that exposure is greater. This gender distribution was also similar to that reported by Tentolouris et al, 2006 where 60.7% were males and 39.3% were females.
The mean age of the study group was 44 years with an age span from <1 to 95 years old. This is higher than the mean age reported by Bukharie & Abdelhadi (35.7y). Approximately 41.5% of the isolates came from patients in the extreme age groups, 21.0% ≥ 60 years and 20.5% ≤ 5 years. Madani et al, 2001 similarly report isolation of 26.1% of MRSA from patients ≥ 60 years and 26.1% from patients ≤ 1 year in another Saudi population. This has likewise been reported by Kuehnert et al, 2005 from the USA whereby most MRSA diagnosis occurred in persons ≥ 65 years of age. Discordantly, Tentolouris et al, 2006 report a much higher mean age of 60.1 years.
The prevalence of MRSA among S. aureus isolates varied from one hospital to another and ranged from 12% to 49.4% with 4 hospitals lying in the range of 27–33%. Hospital A was the hospital from which the highest prevalence was encountered and this is expected due to the fact of it being a referral hospital for most other Ministry of Health hospitals within and around Riyadh. The 27–33% range is quite similar to the 33% reported earlier from Jeddah, Saudi Arabia in 2001 and 2003, as well as 31% in 2005. Yet others report the much lower prevalence of 12% in 2001 from the eastern province. The same prevalence is reported from Nigeria, Kenya and Cameroon. MRSA prevalence is generally reported to be high in North America (43.7% & 43.2%)[30, 34], southern European countries[35, 36], Japan (50–70%), Malaysia, Latin America, Ethiopia, Sri Lanka. In fact, according to the National Nosocomial Infection Surveillance System (NNIS) report, 50% of hospital acquired infections in ICUs in the USA are due to MRSA. In other countries such as Tunisia, Malta, Algeria, Sweden, Switzerland, the Netherlands (the SENTRY participants group, 2001) and Australia (14.9%) on the other hand, it is low. In developing countries, it has always been contended that the inappropriate use of antibiotics for community infections may further increase the pressure to select MRSA and other resistant bacteria. Yet the higher prevalence of MRSA reported from other more developed countries argues against this and perhaps points out to the fact that injudicious use of antibiotics stands true not only for community infections but is true for prescription as well as over the counter medicines. Bacterial resistance threatens our ability to treat both common and serious infections. Although new antibiotics can effectively treat some resistant pathogens and more research is needed to develop novel antimicrobials, bacteria will eventually develop resistance to any antibiotic with time. The misuse and overuse of antibiotics drive the emergence and spread of resistance. Eliminating inappropriate antibiotic use and promoting more judicious use are essential parts of the solution.
For all the acquired isolates, screening for oxacillin resistance has been re-documented using the oxacillin agar screening test using a Mueller-Hinton medium with 4% NaCl and 6 μg/ml oxacillin according to NCCLS guidelines.
Similarly, screening for vancomycin resistance has been carried out using Mueller Hinton agar plates plus 6 μg/ml vancomycin. Until now, no such isolates have been detected nor have they been reported by other researchers in Saudi Arabian hospitals. This is reassuring and indicates that VRSA has not yet set foot in the Saudi hospitals studied unlike reports from Japan, United States, Europe and the Far East. Results of the vancomycin E-test showed that all isolates were susceptible with MICs ranging from 0.25 μg/mL to 3 μg/mL, the higher MICs mainly being from Hospital A.
Antibiotic susceptibility results of the tested isolates
Total susceptibility No. (%) (512)
Inpatient isolates No. (%) (397)
Outpatient isolates No. (%) (115)
Table 1 also shows the percent susceptibilities of the MRSA isolates from inpatients versus isolates from outpatients. Susceptibilities of MRSA against all antibiotics tested was higher for outpatient as opposed to inpatient isolates except for linezolid. This was profoundly evident for gentamicin and trimethoprim/sulfamethoxazole. It was also evident for mupirocin, the local antibiotic used for eradication of the carrier state which is expected due to its use in the hospitals. This was also evident for gatifloxacin, the fluoroquinolone, and again use of fluoroquinolones and thus appearance of resistance against them is expected in hospital isolates. It has been reported in the The Medical Letter On Drugs and Therapeutics that in adequate dosage, sulfamethoxazole/trimethoprim appears to be effective against CA-MRSA, and that resistance is rare, this was the case in the present study where 77.4% of the outpatient isolates were susceptible to sulfamethoxazole/trimethoprim while only 22.2% of the inpatient isolates were susceptible to it.
While the collection of MRSA did not specifically determine community versus nosocomial isolates, it could be generally expected that most outpatient isolates would be community acquired while most inpatient isolates would be nosocomial and thus we can deduce that hospital isolates are more resistant than community isolates.
Percentage susceptibility of MRSA isolates from the studied hospitals to the antibiotics tested by disc diffusion according to CLSI standards
Percent of the most common Antibiotic Susceptibility Patterns per hospital
Antibiotic Susceptibility Pattern
The emergence of antimicrobial resistance among a number of bacterial pathogens changes the way we practice medicine and places some of our patients at risk of dying from their infections. The overuse and misuse of antibiotics are major contributing factors to bacterial resistance; therefore it is incumbent on each of us to use antibiotics judiciously and appropriately. Judicious antibiotic use means that antibiotics are prescribed only when indicated and that the drug chosen is the most narrow spectrum agent that will be effective. Appropriate use means choosing not only the correct antibiotic but also the appropriate dose and duration, factors that can influence the development and carriage of resistant organisms[56, 57]. These "resistotype" data could be complemented with "genotype" data and together, they could be used to exchange profiles across borders rather than actual material exchange.
Trend over time of percent antibiotic susceptibility according to collection period
Isolation period (No.)
Thus, the good news is that bacterial resistance is to some degree reversible. Reducing antibiotic use should be effective in combating resistance development, because resistant bacteria have no competitive advantage in the absence of antibiotic exposure and because colonization with resistant pathogens is usually transient. Because carriage of these resistant bacteria resolves spontaneously, susceptible strains eventually replace resistant strains in the absence of antibiotic exposure. Antibiotic restrictions do not always guarantee that antimicrobial resistance will disappear, however, as demonstrated by a report from the UK . The reasons for this are not clear, although it may be because the determinants of some antibiotic resistance are genetically linked to other resistance determinants.
None of the 512 tested isolates had reduced susceptibility to vancomycin with most MICs lying in the 1 – 1.5 range. Linezolid and quinupristin-dalfopristin are the most effective antibiotics tested against inpatient isolates while gatifloxacin and quinupristin-dalfopristin seem to be the most effective against outpatient isolates. Trends over time show a tendency towards decreased susceptibility to gatifloxacin and linezolid with increasing susceptibility to gentamicin and sulfamethoxazole/trimethoprim.
Quinupristin/dalfopristin and linezolid are two valuable additions to our antimicrobial armamentarium, but resistance has already been described. To preserve their value, their use should be limited to those rare cases where they are clearly needed.
Differences noted in the susceptibility of the isolates from different hospitals probably reflects the different patterns of antibiotic usage and thus development of resistance in these hospitals. Fusidic acid, the local antibiotic, gentamicin and trimethoprim/sulfamethoxazole should not be relied upon for treatment of MRSA infections, at least empirically as the percentage of susceptible isolates is very low. Approximately one forth of the isolates are no longer susceptible to mupirocin used for eradication of the carrier state reflecting resistance developing after widespread use. Keeping these resistotype data in mind while prescribing antibiotics for MRSA infected patients should aid in the prevention of its spread and abiding by the same principles kingdom-wide could limit its deleterious effects. An ongoing study by the same group is genotyping these MRSA isolates for delineating their genetic origins and perhaps their transmission dynamics as they constitute a precious resource for further investigations.
This work was supported by grant AT-24-50 from King AbdulAziz City for Science and Technology, Saudi Arabia.
- Brumfitt W, Hamilton-Miller J: Methicillin-resistant Staphylococcus aureus. New Engl J Med. 1989, 320: 1188-1196.View ArticlePubMedGoogle Scholar
- Baron EJ: The detection, significance, and rationale for control of methicillin resistant Staphylococcus aureus. Clin Microbiol Newslett. 1992, 14: 129-136. 10.1016/0196-4399(92)90082-K.View ArticleGoogle Scholar
- Lieberman JM: Appropriate antibiotic use and why it is important: the challenges of bacterial resistance. Pediatr Infect Dis J. 2003, 22: 1143-1151.View ArticlePubMedGoogle Scholar
- Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, Tenover FC, Zervos MJ, Band JD, White E, Jarvis WR: Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med. 1999, 340: 493-501. 10.1056/NEJM199902183400701View ArticlePubMedGoogle Scholar
- Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, Shah S, Rudrik JT, Pupp GR, Brown WJ, Cardo D, Fridkin SK: Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 2003, 348: 1342-1347. 10.1056/NEJMoa025025View ArticlePubMedGoogle Scholar
- Kitzis MD, Goldstein FW: Monitoring of vancomycin serum levels for the treatment of staphylococcal infections. Clin Microbiol Infect. 2005, 92-95.Google Scholar
- Cui L, Ma K, Sato K, Okuma K, Tenover FC, Mamizuka EM, Gemmell CG, Kim MN, Ploy MC, El Solh N, Ferraz V, Hiramatsu K: Cell Wall Thickening Is a Common Feature of Vancomycin Resistance in Staphylococcus aureus. J Clin Microbiol. 2003, 41: 5-14. 10.1128/JCM.41.1.5-14.2003PubMed CentralView ArticlePubMedGoogle Scholar
- Sieradzki K, Pinho MG, Tomasz A: Inactivated pbp4 in highly glycopeptide-resistant laboratory mutants of Staphylococcus aureus . J Biol Chem. 1999, 274: 18942-18946. 10.1074/jbc.274.27.18942View ArticlePubMedGoogle Scholar
- Harrison CJ: Quinupristin/dalfopristin. Semin Pediatr Infect Dis. 2001, 12: 200-210. 10.1053/spid.2001.24095.View ArticleGoogle Scholar
- Dowzicky M, Talbot GH, Feger C, Prokocimer P, Etienne J, Leclercq R: Characterization of isolates associated with emerging resistance to quinupristin/dalfopristin (Synercid®) during a worldwide clinical program. Diagn Microb Infect Dis. 2000, 37: 57-62. 10.1016/S0732-8893(99)00154-6.View ArticleGoogle Scholar
- Rose CM, Reilly KJ, Haith LR: Emergence of resistance of vancomycin-resistant Enterococcus faecium in a thermal injury patient treated with quinupristin-dalfopristin and cultured epithelial autografts for wound closure. Burns. 2002, 28: 696-698. 10.1016/S0305-4179(02)00105-5View ArticlePubMedGoogle Scholar
- Herrero IA, Issa NC, Patel R: Nosocomial spread of linezolid resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med. 2002, 346: 867-869. 10.1056/NEJM200203143461121View ArticlePubMedGoogle Scholar
- Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, Moellering RC, Ferraro MJ: Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet. 2001, 358: 207-208. 10.1016/S0140-6736(01)05410-1View ArticlePubMedGoogle Scholar
- Pai MP, Rodvold KA, Schreckenberger PC, Gonzales RD, Petrolatti JM, Quinn JP: Risk factors associated with the development of infection with linezolid- and vancomycin resistant Enterococcus faecium. Clin Infect Dis. 2002, 35: 1269-1272. 10.1086/344177View ArticlePubMedGoogle Scholar
- Kayser FH: The quinolones: mode of action and mechanism of resistance. Res Clinic Forums. 1985, 7: 17-27.Google Scholar
- Cederna JE, Terpenning MS, Ensberg M, Bradley SF, Kauffman CA: Staphylococcus aureus nasal colonization in a nursing home: eradication with mupirocin. Infect Control Hosp Epidemiol. 1990, 11: 13-16.View ArticlePubMedGoogle Scholar
- Reagan D, Doebbeling BN, Pfaller MA, Sheetz CT, Houston AK, Hollis RJ, Wenzel RP: Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. Ann Intern Med. 1991, 114: 101-106.View ArticlePubMedGoogle Scholar
- Yun HJ, Lee SW, Yoon GM, Kim SY, Choi S, Lee YS, Choi EC, Kim S: Prevalence and mechanisms of low- and high-level mupirocin resistance in staphylococci isolated from a Korean hospital. J Antimicrob Chemother. 2003, 51: 619-623. 10.1093/jac/dkg140View ArticlePubMedGoogle Scholar
- Kavi J, Andrews JM, Wise R: Mupirocin-resistant Staphylococcus aureus. Lancet. 1987, 2: 1472-10.1016/S0140-6736(87)91179-2.View ArticleGoogle Scholar
- Cookson BD: Mupirocin resistance in staphylococci. J Antimicrob Chemother. 1990, 25: 497-503.View ArticlePubMedGoogle Scholar
- Dupeyron C, Campillo B, Richardet J-P, Soussy C-J: Long-term efficacy of mupirocin in the prevention of infections with meticillin-resistant Staphylococcus aureus in a gastroenterology unit. Journal of Hospital Infection. 2006, 63: 385-392. 10.1016/j.jhin.2006.03.019View ArticlePubMedGoogle Scholar
- Fawley WN, Parnell P, Hall J, Wilcox MH: Surveillance for mupirocin resistance following introduction of routine peri-operative prophylaxis with nasal mupirocin. Journal of Hospital Infection. 2006, 62: 327-332. 10.1016/j.jhin.2005.09.022View ArticlePubMedGoogle Scholar
- Grim SA, Rapp RP, Martin CA, Evans ME: Trimethoprim-Sulfamethoxazole as a Viable Treatment Option for Infections Caused by Methicillin-Resistant Staphylococcus aureus. Pharmacotherapy. 2005, 25 (2): 253-264. 10.1592/phco.188.8.131.52956View ArticlePubMedGoogle Scholar
- Kloos WE, Bannerman TL: Staphylococcus and Micrococcus. Manual of clinical microbiology. Edited by: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH. 1999, 271-276. Washington, DC: American Society for MicrobiologyGoogle Scholar
- National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial susceptibility testing. NCCLS approved standard M100-S14. 2004, NCCLS, Wayne, PA USAGoogle Scholar
- van Belkum A, Vandenbergh M, Kessie G, Qadri H, Lee G, vanDen Braak N, Verbrugh H, Al-Ahdal MN: Genetic homogeneity among methicillin-resistant Staphylococcus aureus strains from Saudi Arabia. Microbial Drug Resistance. 1997, 3 (4): 365-369.View ArticlePubMedGoogle Scholar
- Madani TA, Al-Abdullah NA, Al-Sanousi AA, Ghabrah TM, Afandi SZ, Bajunid HA: Methicillin-resistant Staphylococcus aureus in two tertiary-care centers in Jeddah, Saudi Arabia. Infect Control Hosp Epidemiol. 2001, 22: 211-216. 10.1086/501891View ArticlePubMedGoogle Scholar
- Bukharie HA, Abdelhadi MS: The epidemiology of Methicillin-resistant Staphylococcus aureus at a Saudi University Hospital. Microb Drug Resist. 2001, 7: 413-416. 10.1089/10766290152773428View ArticlePubMedGoogle Scholar
- Tentolouris N, Petrikkos G, Vallianou N, Zachos C, Daikos GL, Tsapogas P, Markou G, Katsilambros N: Prevalence of methicillin-resistant Staphylococcus aureus in infected and uninfected diabetic foot ulcers. Clin Microbiol Infect. 2006, 12: 186-189. 10.1111/j.1469-0691.2005.01279.xView ArticlePubMedGoogle Scholar
- Kuehnert MJ, Hill HA, Kupronis BA, Tokars JI, Solomon SL, Jernigan DB: Methicillin-resistant-Staphylococcus aureus hospitalizations, United States. Emerging Infectious Diseases. 2005, 11: 868-872.View ArticlePubMedGoogle Scholar
- Austin TW, Austin MA, McAlear DE, Coleman BT, Osaba AO, Thagafi AO, Lamfon MA: MRSA prevalence in a teaching hospital in Western Saudi Arabia. Saudi Med J. 2003, 24: 1313-1316.PubMedGoogle Scholar
- Al-Haj-Hussein BT, Al-Shehri MA, Azhar EA, Ashankyty IM, Osoba AO: Evaluation of 2 real-time PCR assays for the investigation of mecA gene in clinical isolates of MRSA in western Saudi Arabia. Saudi Med J. 2005, 26: 759-762.PubMedGoogle Scholar
- Kesah C, Ben Redjeb S, Odugbemi TO, Boye C, Dosso M, Ndinya JO, Achola S, Koulla-Shiro C, Benbachir M, Rahal K, Borg M: Prevalence of methicillin-resistant Staphylococcus aureus in eight African hospitals and Malta. Clin Microbiol Infect. 2000, 9: 153-156. 10.1046/j.1469-0691.2003.00531.x.View ArticleGoogle Scholar
- Hoban DJ, Biedenbach DJ, Mutnick AH, Jones RN: Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000). Diagn. 2003, 45: 279-285.Google Scholar
- Voss A, Milatovic D, Wallrauch-Schwarz C, Rosdahl VT, Braveny I: Methicillin-resistant Staphylococcus aureus in Europe. Eur J Clin Microbiol Infect D is. 1994, 13: 50-55. 10.1007/BF02026127.View ArticleGoogle Scholar
- European Antimicrobial Resistance Surveillance System: Annual Report. On-going surveillance of S. pneumoniae, S. aureus, E. coli, E. faecium, E. faecalis. 2002, Bilthoven EARSSGoogle Scholar
- Takeda S, Yasunaka K, Kono K, Arakawa K: Methicillin resistant Staphylococcus aureus (MRSA) isolated at Fukuoka University Hospital and hospitals and clinics in the Fukuoka city area. Int J Antimicrob Agents. 2000, 14 (1): 39-43. 10.1016/S0924-8579(99)00148-XView ArticlePubMedGoogle Scholar
- Hanifah YA, Hiramatsu K, Yokota T: Characterization of methicillin-resistant Staphylococcus aureus associated with nosocomial infection in the University Hospital, Kuala Lumpur. J Hosp Infect. 1992, 21: 15-28. 10.1016/0195-6701(92)90150-KView ArticlePubMedGoogle Scholar
- Gales Ac, Jones RN, Pfaller MA, Gordon KA, Sader HS: Two-year assessment of the pathogen frequency and antimicrobial resistance patterns among organisms isolated from skin and soft tissue infections in Latin American Hospitals: results from the SENTRY antimicrobial surveillance program, 1997–1998. SENTRY Study Group. Int J Infect Dis. 2000, 4: 75-84. 10.1016/S1201-9712(00)90098-5View ArticlePubMedGoogle Scholar
- Geyid A, Lemeneh Y: The incidence of methicillin-resistant Staphylococcus aureus strains in clinical specimens in relation to their β-lactamase producing and multiple drug resistance properties in Addis Ababa. Ethiop Med J. 1991, 29: 149-161.PubMedGoogle Scholar
- Hart CA, Kariuki S: Antimicrobial resistance in developing countries. BMJ. 1998, 317: 647-650.PubMed CentralView ArticlePubMedGoogle Scholar
- Salgado CD, Farr BM, Calfee DP: Community acquired Methicillin eresistant Staphylococcus aureus : A meta analysis of prevalence and risk factors. Clin Infect Dis. 2003, 36: 131-139. 10.1086/345436View ArticlePubMedGoogle Scholar
- SENTRY participants group : Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY antimicrobial susceptibility program 1997–1999. Clin Infect Dis. 2001, S114-132. Suppl 2Google Scholar
- Nimmo GR, Coombs GW, Pearson JC, O'Brien FG, Christiansen KJ, Turnidge JD, Gosbell IB, Collignon P, McLaws M-L, : Methicillin-resistant Staphylococcus aureus in the Australian community: an evolving epidemic. MJA. 2006, 184: 384-388.PubMedGoogle Scholar
- Hiramatsu K, Hanaki H, Ino T, Whitehouse T, Singer M, Bellingan G: Methicillin resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 1997, 40: 135-136. 10.1093/jac/40.1.135View ArticlePubMedGoogle Scholar
- Tenover FC: Implications of vancomycin-resistant Staphylococcus aureus. J Hosp Infect. 1999, 43 (suppl): 3-7. 10.1016/S0195-6701(99)90060-9.View ArticleGoogle Scholar
- Yamaguchi K, Ohno A: Investigation of the susceptibility trends in Japan to fluoroquinolones and other antimicrobial agents in a nationwide collection of clinical isolates: a longitudinal analiysis from 1994 to 2002. Diagnostic Microbiology and Infectious Disease. 2005, 52: 135-143. 10.1016/j.diagmicrobio.2005.02.009.View ArticlePubMedGoogle Scholar
- Panhotra BR, Saxena AK, Al-Mulhim AS: Prevalence of methicillin-resistant and methicillin-sensitive Staphylococcus aureus nasal colonization among patients at the time of admission to the hospital. Ann Saudi Med. 2005, 25 (4): 304-308.PubMedGoogle Scholar
- Matynia B, Młodzinska E, Hryniewicz W: Antimicrobial susceptibility patterns of Staphylococcus aureus in Poland obtained by the National Quality Assurance Programme. Clin Microbiol Infect. 2005, 11: 379-385. 10.1111/j.1469-0691.2005.01105.xView ArticlePubMedGoogle Scholar
- Wilson AP, Cepeda JA, Hayman S, Whitehouse T, Singer M, Bellingan G: In vitro susceptibility of Gram-positive pathogens to linezolid and teicoplanin and effect on outcome in critically ill patients. J Antimicrob Chemother. 58 (2): 470-473.View ArticleGoogle Scholar
- Kresken M, Hafner D, Schmitz F-J, Wichelhaus TA, on behalf of the Working Group for Antimicrobial Resistance of the Paul-Ehrlich-Society for Chemotherapy: Prevalence of mupirocin resistance in clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis: results of the Antimicrobial Resistance Surveillance Study of the Paul-Ehrlich-Society for Chemotherapy, 2001. International Journal of Antimicrobial Agents. 2004, 23: 577-581. 10.1016/j.ijantimicag.2003.11.007View ArticlePubMedGoogle Scholar
- Udo EE, Jacob LE, Mathew B: The spread of a mupirocin-resistant/methicillin-resistant Staphylococcus aureus clone in Kuwait hospitals. Acta Tropica. 2001, 80: 155-161. 10.1016/S0001-706X(01)00171-1View ArticlePubMedGoogle Scholar
- Echániz-Aviles G, Velázquez-Meza ME, Aires-de-Sousa M, Morfín-Otero R, Rodríguez-Noriega E, Carnalla-Barajas N, Esparza-Ahumada S, de Lencastre H: Molecular characterisation of a dominant methicillin-resistant Staphylococcus aureus (MRSA) clone in a Mexican hospital (1999–2003). Clin Microbiol Infect. 2006, 12: 22-28. 10.1111/j.1469-0691.2005.01283.x.View ArticlePubMedGoogle Scholar
- Bastos MCF, Mondino PJJ, Azevedo MLB, Santos KRN, Giambiagi-deMarval M: Molecular characterization and transfer among Staphylococcus strains of a plasmid conferring high level resistance to mupirocin. Eur J Clin Microbiol Infect Dis. 1999, 18: 393-398. 10.1007/s100960050306View ArticlePubMedGoogle Scholar
- Caieraão J, Berquó L, Dias C, d'Azevedo PA, Alegre P: Decrease in the incidence of mupirocin resistance among methicillin-resistant Staphylococcus aureus in carriers from an intensive care unit. Brazil Am J Infect Control. 2006, 34: 6-9. 10.1016/j.ajic.2005.08.006.View ArticleGoogle Scholar
- Scheld WM: Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis. 2003, 9: 1-9.PubMed CentralView ArticlePubMedGoogle Scholar
- Craig WA: Does the dose matter?. Clin Infect Dis. 2001, S233-237. 10.1086/321854. Suppl 3View ArticleGoogle Scholar
- Enne VI, Livermore DM, Stephens P, Hall LM: Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction. Lancet. 2001, 357: 1325-1328. 10.1016/S0140-6736(00)04519-0View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.